phentermine 37.5 free shipping
Named PR Week's 2006 "International Consultancy of the Year," FD's 500 professionals advise phentermine 37.5 free shipping from 17 offices in every major business center in the world. FD is a division of FTI Consulting, a global corporate advisory firm specializing in helping phentermine 37.5 free shipping overcome complex business challenges in areas such as restructuring, litigation, mergers and acquisitions, regulatory investigations, and reputation management, among many others. For more information, please visit www.fd.com. About Gibraltar Associates Gibraltar Associates is a consultancy specializing in risk and reputation management, public affairs and business development for phentermine 37.5 free shipping worldwide. Gibraltar Associates blends expertise from diverse consulting genres to offer phentermine 37.5 free shipping a truly holistic approach to solving challenges confronting the business. Our mission is to provide world class counsel to phentermine 37.5 free shipping and implement those ideas to produce a tangible business result. The company is based in Washington, D.C., with an office in Los Angeles. For more information, please visit: www.Gibraltar or call 202 879 5808. Forward Looking Statements This release contains forward looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be de listed from the Nasdaq Global Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10 Q for the quarter ended September 30, 2007. Readers are cautioned not to place undue reliance on any forward looking statements, which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events. ... phentermine 37.5 free shipping